TORONTO, ONTARIO -- (Marketwired) -- 11/26/14

Hemostemix Inc. (the "Corporation") (TSX VENTURE:HEM) announces the TSX Venture Exchange ("Exchange") has issued a final Exchange Bulletin approving Technical Ventures RX Corp.'s (TSX VENTURE:TIK.P) previously announced qualifying transaction with TheraVitae Inc., pursuant to which the parties amalgamated to form a new entity under the Business Corporations Act (Alberta) called "Hemostemix Inc.". Trading in the common shares of the Corporation on the Exchange is expected to resume at the opening of markets on or around Thursday, November 27, 2014 under the symbol "HEM".

"I would like to recognize the perseverance of all shareholders and team effort by all involved to facilitate the successful conclusion of the reverse takeover. This is another important milestone for the Corporation. With the successful recent initiation of our phase II clinical trial in critical limb ischemia and the recent appointment of Dr. Elmar Burchardt (former Vice President of Regenerative Medicine at Pfizer) as the new CEO, the Corporation has made a significant transition," stated Board Chairman, Bill Baker.

Dr. Elmar Burchardt stated, "I just returned from Israel where I engaged with our scientists and reviewed the Corporation's science and business opportunities in depth. I am very pleased to report the Corporation has many strengths on which to build going forward and I am very excited about our prospects for the future."

Neither the TSX Venture Exchange, Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and has neither approved nor disapproved of the contents of this press release.

Contacts:
Hemostemix Inc.
Dr. Elmar Burchardt
CEO
(339) 234-3533

Hemostemix Inc.
C.W. (Bill) Baker
Chairman of the Board
(403) 818-7672